text:
Global Summit on Pharmacology and Therapeutics
European Summit on Pharmacology and Toxicology
Subject wise Global Events
Physics & Materials Science
As per available reports about 325 journals, 150 Conferences, 30 workshops are presently dedicated exclusively to molecular pharmacology and about 215000 articles are being published on the current trends in molecular pharmacology. In terms of research annually, USA, India, Japan, Brazil and Canada are some of the leading countries where maximum studies related to molecular pharmacology are being carried out. As reported in above articles,Molecular Pharmacology deals with publishing the findings which are derived from application of innovative structural biology, molecular biology, biophysics, genetics, physiology and biochemistry to basic problems of pharmacology that provide mechanistic insights which are important for the fields of toxicology and pharmacology.
The Journal of Biochemistry & Pharmacology is an academic journal – hosted by OMICS International – a pioneer in open access publishing–and is listed among the top 10 journals in molecular pharmacology. Each year research scientists have noticed a rise in the number of congresses being held in this field. The Journal of Biochemistry & Pharmacology provides a unique platform to researchers and scientist to explore the advanced and latest research developments in the field of Biochemistry and Pharmacology, thus bridging the gap between researchers and young scientists.
OMICS International – a pioneer in organizing international conferences, 3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing during December 08-10, 2014 at San Francisco, USA. This conference includes 11 tracks and 71 sessions and is designed to offer comprehensive sessions that prefers to current issues in Medicinal Chemistry & Computer Aided Drug Designing.
Our Group hosts over 700 leading-edge peer reviewed Open Access Journals and organize over 3000 International Conferences annually all over the world. Our Group journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 50000 eminent personalities that ensure a rapid, quality and quick review process. Our Group signed an agreement with more than 1000 International Societies to make healthcare information Open Access.
List of major molecular pharmacology and related journals
Journal of Biochemistry & Pharmacology
Indian Journal of Pharmacology, Molecular and Cellular Pharmacology
Tropical Journal of Pharmaceutical Research
International Journal of Pharmaceutical Sciences and Drug Research
List of major molecular pharmacology and related Conferences
3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
Molecular Pharmacology - Gordon Research Conferences
5th Molecular Pharmacology Meeting
International Conference on Medicinal Chemistry and Molecular Pharmacology
List of major molecular pharmacology and related Research Centres
Pharmacological Sciences Predoctoral Research
Brain Research Institute
RNA and NTI Therapeutics Institute
Central Drug Research Institute, Rollins Research Center
This page will be updated regularly.
This page was last updated on January 19, 2020
Subject wise Open Access Journals


The manuscript must be in an electronic format. We will accept the document in MS Word, OpenOffice, Corel Draw, inDesign, Pagemaker and a variety of other formats The Images/photos can be posted to us and we will scan them for you. If you are going to scan them yourself, then please do so at the highest possible resolution. 300 DPI is the minimum for a decent quality print, but we would prefer them to be at 600 DPI. We prefer the files to be zipped when emailed to us. You can also post them to us on CD We prefer images to be linked and not imbedded in the document. We will consider all submissions. Not all submissions will be accepted for publishing. We reserve the right to reject a manuscript without providing any reasons and at our sole discretion We will accept manuscripts for printing (and not publication) for a fee.
Other conditions and procedures will be sent to prospective authors via email.


Shortly after I had a double mastectomy, I got lymphedema in my arms. I was devastated. I knew going in what it was, and I was terrified.
Put very simply, the lymphatic system provides cells with nutrients and acts as a means of waste removal. We need it to survive. However, the same system will also carry cancer cells to other parts of the body, which is called metastasis. Cancer cells get trapped in lymph nodes and cause secondary tumors, which is why surgeons will err on the side of caution to keep the cancer from coming back. Curing cancer is their focus after all.
When the lymph system becomes blocked due to traumatic injury, such as removal of lymph nodes during surgery, the fluids that normally drain become blocked. The blockage causes the affected limb to swell. In my case, I felt a heaviness in my arm. One arm was larger than the other. It was sore. It ached. It was painful to touch. I felt little lumps under the skin that I knew weren't there before.
So what do I do now?How am I going to live with something I was so afraid of? Something that makes me so angry and depressed? Something that is affecting the quality of my life—and will for the rest of my life.
One of my surgeons found Dr. Emily Iker who specializes in Lymphatic Diseases. Luckily for me, she is located right here in Santa Monica. Dr. Iker is the one who helped me begin healing, both emotionally and physically.
In my case--which thank the Lord is relatively mild—Iker uses Manual Lymphatic Drainage and a pneumatic pump. I try to see her at least once every 4-6 weeks. It ain't cheap, and I'm so grateful I can afford it. She fitted me with compression sleeves that I need to wear most days and especially on airplanes. They're hot and uncomfortable. I can't lift more than a few pounds. I need to be careful not to get a cut that might develop into an infection. I have to have blood drawn from the less affected arm. The same goes with blood pressure cuffs. I have to stay out of hot showers, steam rooms and jacuzzis. It was very difficult for me to work in the New Orleans heat. The list goes on.
After my diagnosis, Iker introduced me to Bill Repicci the Executive Director of the Lymphatic Education & Research Networkof (LE&RN).
Bill told me that up to 10 million Americans suffer from lymphedema. More than muscular dystrophy, multiple sclerosis, ALS, Parkinson's and AIDS—COMBINED. When I heard those numbers, my jaw dropped. Bill also told me that many veterans who have suffered traumatic injuries on the battlefield can develop lymphedema. But, it is also genetic.
I decided to take all the negative feelings I have about lymphedema and turn it into helping other people who are suffering, in many cases much worse than I am. I became an official Ambassador for LE&RN.
As an ambassador, I want to educate the public about this disease. There is a host of information available on LE&RN's website, lymphaticnetwork.org. We are trying to spread the word about this disease—and make no mistake this is not about cosmetics. This is a chronic degenerative and inflammatory disease.
Incredibly, many people, including doctors and nurses outside the cancer realm, have never even heard of it. In some cases, even people who suffer from lymphedema have never been properly diagnosed. And early diagnosis is key. Appropriate treatment is essential to limiting progression of the swelling. When the swelling goes unchecked, the tissues harden and mobility is severely compromised. It becomes much more difficult to treat.
In addition to raising awareness, we want to raise money for research. Recently, through LE&RN's support, Dr. Karina Yaniv and her colleagues at the Weizmann Institute of Science in Israel revealed how the lymphatic system develops in the embryo. And for the first time they managed to grow lymphatic cells in the lab!
I and all of us at LE&RN so appreciate the opportunity you have given us to get the word out about a disease that affects the lives of millions of people.


Pinda Swedana is a traditional Ayurvedic therapy with profound healing and renewal potential. In this therapy, warm cloth boluses, prepared with herbs, milk, and rice, are massaged into the entire body. The warmth of the boluses opens the channels and allows the herbalized milk to penetrate deeply into underlying tissues. Pinda Swedana enhances circulation, improves muscle tone, strengthens the nervous system, and restores vitality to the entire body.


50% because of divorce and medical. Also, foreclosures and bankruptcies, non-verifiable income, identity theft, low credit score and debt ratio, lawsuits and tax liens, student loans. People lose jobs and fail in businesses. As a result people suffer and cannot qualify for a loan.
To help people to improve their quality of life with profound knowledge.
Profound knowledge is life changing.
The only requirement we have is 15% for down payment.
If you do not qualify for traditional financing and want to buy a home now, 15% down is all you need to buy your dream home!
We do not verify your employment as well as your income.
There is no application to fill out and no application fee.
We do not check your credit. No matter if you have low FICO score, bad credit with negative items on your report or no credit at all.
Buyers with no SS# accepted.
Vlad helped me when the banks would not. I didn't think I could buy a home because of my credit issues, even though I had the money. Vlad helped me to buy my home and move in right away. I would recommend him to anyone.
I was tired to rent and no options to buy a home because I couldn't get a loan. These people opened my eyes and showed me this owner financing option that worked for me perfectly. Thank you Vlad and Anastasia.
If we are not available to answer the phone, please leave us a message and we will contact you as soon as possible.


text:
In Praise of Idleness: A Timeless Essay
Author(s): Russell, Bertrand, Greive, Bradley Trevor
"Most People Would Die Sooner Than Think"
Considered "the Voltaire of his time", Bertrand Russell was a fearless iconoclast who stood unbowed before political and religious leaders; his disdain for conventional thinking and accepted beliefs set him apart from his academic peers and at odds with the authorities throughout his long and storied life.
In his celebrated essay In Praise Of Idleness, Russell champions the seemingly incongruous notion that realising our full potential - and thus enjoying the greatest possible success and happiness - is not accomplished by working harder or smarter, but through harnessing the extraordinary power of idleness.
Russell's penetrating insights and exquisite turns of phrase feel as fresh and relevant today as when they were first written. Arguing that we can achieve far more by doing far less, and that traditional wealth accumulation is a form of cultural and moral poverty, Russell demands greater depth from our age of abundant creativity and heralds the next wave of enlightened entrepreneurs.
Replete with a new introduction and afterword, and interspersed with comic illustrations, informative notes plus a curated selection of Russell's best quotes from many of his acclaimed works, this unique edition of In Praise Of Idleness is given new life by New York Times-bestselling author and internationally acclaimed humourist Bradley Trevor Greive.
Bertrand Russell, 3rd Earl Russell, OM, FRS was a Welsh philosopher, logician, mathematician, historian, writer, social critic and political activist. He was awarded the Nobel Prize for Literature in 1950.
Bradley Trevor Greive (BTG) is a New York Times bestselling author who became a household name
after writing The Blue Day Book. He has since gone on to become one of the world's most successful humour authors, and his books have sold more than 25 million copies in 29 languages and 115 countries. Tasmanian-born, BTG currently divides his time between Australia and the USA in order to placate his American in-laws.
Publisher: Black Inc

redpajama_set_name: RedPajamaCommonCrawl


text:
Washington seizes on UN report to threaten Syria
The Bush administration has seized upon the release of a United Nations report implicating senior Syrian and Lebanese officials in last February's assassination of Lebanon's former prime minister and billionaire businessman Rafik Hariri as a pretext for escalating its threats against Damascus.
Backed by Britain, its principal ally in the Iraq war and occupation, Washington is pressing for a meeting of the United Nations Security Council this week to consider imposing international sanctions against the Syrian regime of President Bashar Assad.
The UN report cannot be "left lying on the table," US Secretary of State Condoleezza Rice said in a joint BBC interview with her British counterpart, Foreign Minister Jack Straw. "This really has to be dealt with."
"The report indicates that people of a high level of this Syrian regime were implicated," declared Straw. "We also have evidence from the Mehlis report of false testimony being given by senior people in the regime. This is very serious."
The report, prepared by German prosecutor Detlev Mehlis, represents the interim findings of the UN-mandated investigation. Much of it consists of a description of the political situation in Lebanon in the period leading up to the assassination. The document makes clear that there does not yet exist sufficient evidence to charge anyone with Hariri's killing, and that a "presumption of innocence" applies to those supposedly implicated.
Calling the report "politically biased," the Syrian regime has vigorously denied the charge that top-level officials—including two members of President Assad's family—were involved, and that it deliberately misled the UN investigators.
"It is a political statement against Syria based on allegations by witnesses known for their hostility to Syria," declared information minister Mehdi Dakhlallah Friday in an interview with the Qatar-based television network, Al Jazeera.
At a Saturday news conference in Damascus, Syrian Foreign Minister Riyad Dawoodi also condemned the report as politically biased, based upon "presumptions and allegations," but "no proof."
"There's a presumption taken by the (UN) commission that the very presence of Syrian troops and the Syrian security organs in Lebanon is something which should imply so and so and so," he said. "You cannot put any weight on the idea (that) because you are present in Lebanon, everything happening in Lebanon ... should be done according to your knowledge and you know about it."
The foreign minister continued: "The report has a conclusion that this operation, the assassination of late Prime Minister Hariri, cannot be done without a means, a very sophisticated means which belongs to a highly equipped security organ. And you just look around you, who is very, very well equipped?"
While Dawoodi did not elaborate, the statement reflected suspicions within the region that the Israeli intelligence service, Mossad, may have organized the assassination in order to destabilize both Lebanon and Syria and create the conditions for US military actions against the Damascus regime.
Just before the report's release, one of the principal witnesses for the commission's allegations against Syrian officials was arrested in Paris. The Lebanese government charges that he gave the UN panel false testimony.
Mohammad Zuheir al-Siddiq, a Syrian émigré residing in France, was detained on an international warrant and faces extradition to Lebanon. Siddiq was reportedly the principal source for claims that Syrian officials met to discuss the assassination. Damascus has charged the former soldier with fraud and desertion. He had lived since 1996 in Lebanon, where he was reportedly arrested for theft.
While United Nations Secretary General Kofi Annan has extended the UN investigation until December 15, neither Washington nor London appear willing to wait that long to demand conclusions and punitive action. The extraordinary tension whipped up by the Bush administration over what are the preliminary findings of an investigation commission leaves no doubt as to Washington's determination to exploit the issue.
In a revealing comment, the German prosecutor Mehlis told the German newsweekly Stern, "I never wanted to be compared with Hans Blix. But now I know how he must have felt." While not providing a shred of evidence that Iraq had weapons of mass destruction, the UN's chief weapons inspector Blix produced a report accusing the Iraqi regime of failing to give sufficient cooperation. The report was seized upon by the US to promote its case for an unprovoked war.
In an article published Sunday, the Israeli daily Haaretz pointed to the way in which these new findings against Syria are being manipulated for similar political purposes:
"[W]hy was an incomplete interim report necessary?" Haaretz asked. "The answer lies in Washington and Beirut. Washington needs some sort of incriminating evidence against Syria to goad Damascus, regarded as abetting terror in Iraq, by means of the UN Security Council. The Syria Accountability Act, which allowed President George W. Bush to impose partial economic sanctions, is not harsh enough, according to the US administration. US trade with Syria is about $300 million a year, to Europe's more than $7 billion. Bush therefore needs European cooperation to get Syria's attention."
Beyond sanctions, there are mounting indications that the Bush administration is considering opening up a second front in its war of aggression in Iraq. In an article entitled "Plans: Next, War on Syria," Newsweek magazine reported earlier this month: "Deep in the Pentagon, admirals and generals are updating plans for possible US military action in Syria and Iran.... The Defense Department unit responsible for military planning for the two troublesome countries is 'busier than ever,' an administration official says."
There have been press reports of US attacks on Syria, some attributed to fighting in western Iraq spilling over the border and others to deliberate operations by American special forces units.
Just days before the release of the UN panel's interim report, Secretary of State Rice appeared before the Senate Foreign Relations Committee to testify on US policy in the Middle East. Asked if the administration was preparing for military action against Syria, she replied, "I don't think the president ever takes any of his options off the table concerning anything to do with military force."
Pressed by Republican Senator Lincoln Chafee of Rhode Island as to whether such action would not require a separate congressional resolution, Rice demurred, "I don't want to try and circumscribe presidential war powers. And I think you'll understand fully that the president retains those powers in the war on terrorism and in the war on Iraq."
Senator Christopher Dodd (Democrat-Connecticut) pressed further: "Is there a White House Syrian group, for instance, that's meeting? Are we planning some action in Syria that we ought to be aware of in this committee? Are we considering military action against Syria?"
Rice replied only, "I'm not going to get into what the president's options might be."
While the US military is already stretched to near the breaking point by the ongoing war in Iraq, the launching of a new military adventure in Syria cannot be ruled out. Facing an increasingly desperate political crisis in Washington, the Bush administration could well see another eruption of militarism as a way out.
There are clearly sharp divisions within the administration over what policy to pursue. The Times of London reported October 15 that US diplomats had proffered a deal to Damascus modeled on the arrangement worked out between the Bush administration and the Gaddafi regime in Libya. Syria would agree to cooperate fully with the UN probe—including turning over officials charged in the Hariri case—stop all activity in Lebanon and effectively seal its border with Iraq. In return, Washington would offer normalized relations.
According to several reports, however, the newspaper article was itself the product of a deliberate leak from elements within the administration who opposed any such deal and sought to sink it by making it public.
Among the most opposed to such a compromise is Washington's ambassador to the United Nations John Bolton, who, as former under secretary of state for arms control and international security, attempted to make the case that Syria was developing "weapons of mass destruction" while maintaining close ties to "terrorist groups." Speaking in London October 14, Bolton declared that Syria "should be dealt with very seriously."
The Assad regime has taken repeated steps aimed at placating Washington. In the aftermath of the September 11, 2001 attacks, Bashar Assad sent official condolences and provided information and assistance to US intelligence, including allowing suspects to be transported under the CIA's "rendition" program to be tortured in Syria.
While Damascus publicly opposed the Iraq invasion, as a nonpermanent member of the UN Security Council, Syria voted in 2001 for the resolution demanding that Baghdad allow the return of the UN weapons inspectors, and in 2003 for the measure authorizing UN cooperation with the US occupation in Iraqi reconstruction.
The policy represented a continuation of the cooperation offered by Bashar's father, President Hafiz al-Assad, who provided direct support for the US in the first Persian Gulf war.
Yet the predominant forces within the current US administration have rejected all concessions by Damascus as meaningless. They appear determined to press for regime change as part of a US strategy to impose its strategic dominance over the region.
Playing a major role in these calculations is the tight connection between US policy in the Middle East and that pursued by the right-wing Likud bloc in Israel. Among those who prepared the US war in Iraq were top officials who worked as Likud advisers. Among them were David Wurmser, Vice President Dick Cheney's advisor on the Middle East, Douglas Feith, the former undersecretary for policy at the US Defense Department, and Richard Perle, the former chairman of the Pentagon's Defense Policy Board.
Together, these three drafted a 1996 document for incoming Israeli Prime Minister Benjamin Netanyahu titled "A Clean Break: a New Strategy for Securing the Realm," which advocated a policy of "rolling back Syria." This Likud policy has been largely adopted by Washington.
If the Bush administration decides to carry out limited military action—bombings, limited border attacks etc.—or a full-scale invasion and occupation, the consequences would prove catastrophic. While the Syrian military would no doubt collapse under such an attack, US forces would face another intractable war of resistance which would enjoy widespread support from the country's 18 million people and the broad masses throughout the Arab and Muslim world.
Moreover, there is no credible pro-American opposition in Syria. The Reform Party of Syria, backed by Washington and based in the US, is virtually unknown in the country itself. To the extent that the Assad regime faces any real opposition, it is from Islamic fundamentalists who support the insurgency in Iraq, or from sections of the military and intelligence forces that are supposedly implicated in the Hariri assassination.
While one can only speculate as to who was ultimately responsible for the murder of Hariri, a stench of hypocrisy surrounds the US-led campaign to use the killing to isolate and undermine the Syrian regime.
Foreign Secretary Jack Straw declared: "The international community can show that it is standing up for justice. You simply cannot tolerate a situation where one state decides to deal with problems of another state by assassinating the other state's leaders."
Yet both Washington and London have tolerated Israel's use of assassination as a state policy in the region for many years. Just last month, the press reported that Prime Minister Ariel Sharon convened an emergency meeting of the Israeli cabinet which voted to resume its practice of "targeted assassinations." On the very night the UN report was released, an Israeli assassination squad sneaked into the West Bank village of Anabat and shot to death Raéd Ahmad Shehada, a local leader.
He was only the latest in a long line of victims of Israeli assassinations aimed against the Palestinian leadership, from the murder of Abu Jihad in Tunis in 1988 to the more recent killings of Hamas founder Sheikh Ahmad Yassin in March 2004 and his successor, Dr. Abdel Aziz al-Rantissi, barely one month later.
Needless to say, such killings invoke no calls for sanctions, much less threats of military action, from either Washington or London.


text:
Facts About Livermorium
By Live Science Staff
Livermorium (Image credit:  Galyna Andrushko  | Shutterstock)
Atomic Number: 116 Atomic Symbol: Lv Atomic Weight: [293] Melting Point: Unknown Boiling Point: Unknown
Word origin: Livermorium is named for the Lawrence Livermore National Laboratory in California. The name was officially given by the International Union of Pure and Applied Chemistry on May 31, 2012; prior to that, it was known as ununhexium — one-one-six in Latin.
Discovery: Livermorium was created by scientists at the Joint Institute for Nuclear Research in Dubna, Russia, in 2000. On December 6 of that year, it was jointly announced by the Russian scientists and scientists at the Lawrence Livermore National Laboratory.
Properties of livermorium
Livermorium is a radioactive, artificially produced element about which little is known. It is expected to be a solid and classified as a metal. It is a member of the chalcogen group.
Livermorium has four isotopes with known half-lives, all of which decay through alpha decay. The most stable is 293Lv with a half-life of about 53 milliseconds.
The atomic weight for manmade transuranium elements is based on the longest-lived isotope. These atomic weights should be considered provisional since a new isotope with a longer half-life could be produced in the future. [See Periodic Table of the Elements]
Sources of livermorium
The scientists who created livermorium bombarded curium atoms with calcium ions, producing livermorium and four free neutrons.
Uses of livermorium
Since only a few atoms of livermorium have ever been made, it has no practical uses outside of scientific study.
(Sources: Los Alamos National Laboratory, Jefferson Lab)
Live Science Staff
For the science geek in everyone, Live Science offers a fascinating window into the natural and technological world, delivering comprehensive and compelling news and analysis on everything from dinosaur discoveries, archaeological finds and amazing animals to health, innovation and wearable technology. We aim to empower and inspire our readers with the tools needed to understand the world and appreciate its everyday awe.


text:
Tag Archives: 5d mark 2
No 'Room for noise
9th June 2010 Musings5d mark 2, Adobe, Canon, Lightroom, London, noise reductionnickminers
Adobe finally released Lightroom 3 today, after an extensive beta testing period during which we were shown tantalising glimpses of the new features. However, by far the most impressive of the added goodies is the improved noise reduction. I've included some examples below.
Borough Market, EOS 5D Mark II, ISO 3200
This photo was taken at ISO 3200 on my Canon EOS 5D Mark II, shortly after I bought it, as part of a series of photos of Borough Market in London. All the photos in the set were taken at the same ISO, which allowed me to capture much of the activity and goods on sale without having to use flash.
Borough Market, EOS 5D Mark II, ISO 3200 (no noise reduction - 100% crop)
Here is a 100% crop of the same shot with no noise reduction applied (all sliders set to zero); for ISO 3200 it's pretty good, showing off the low-light capabilities the 5DII is famous for.
Borough Market, EOS 5D Mark II, ISO 3200 (after noise reduction - 100% crop)
After applying noise reduction, the chroma noise has all but vanished, and only a hint of luminance noise remains, with (in my opinion) suggestions of film grain.
Borough Market, EOS 5D Mark II, ISO 3200 (after noise reduction)
The full photo, after noise reduction has been applied. It's hard to tell the difference at this size, so here's an example of an ISO 6400 shot that has been adjusted with Lightroom 3:
Starry night, ISO 6400, no NR
The chroma noise, even at this smaller size, is obvious, especially in the cloud and on the right-hand illuminated tree at the bottom of the picture.
Starry night, ISO 6400, after NR
The difference here is plain. A huge improvement over the original.
I now feel I can more confidently use ISO 6400 more on my camera now; technically it does go up to ISO 25,600 but I would have to try that out in Lightroom before deciding whether it's a realistic option.
Three legs bad?
21st December 2008 Galleries5d mark 2, architecture, Cambridge, Canon, England, rants, tripods, UKnickminers
I went to Cambridge yesterday, primarily to hand over my old 5D to its new owner, but also to take some photos with the new Mark II while allowing my friend to try out his new toy at the same time. The vibrant colours of the market were a good source of photos, but we were both rather disappointed by the attitude of the university staff. Whilst I was framing a photo (hand-held, I should add) outside Kings College Chapel, I was told we weren't allowed to use tripods on the university grounds. I pointed out I wasn't using the tripod, but as it was standing next to me, that counted as 'using' it apparently. When I asked why not, all we got was 'it's the rules'.
Something similar has happened to me before, next to the London Eye, where I concede that using a tripod could be construed as an obstruction given how busy it is there, but as we were pretty much the only people outside the chapel I can't for the life of me understand why such a restriction would be in place. Of course we both left the grounds immediately, pondering the increasingly suspicious attitude of people towards photographers in general.
Anyway if you want to see the pictures I did manage to take, with or without a tripod, look no further.
Low light, low noise
19th December 2008 Galleries5d mark 2, Apple, Borough market, Canon, England, Equipment/Software, Jacobs, lens, London, Sigma, UKnickminers
I'm thoroughly enjoying getting to know the new camera, and in conjunction with Sigma's increasingly impressive 105mm EX-DG Macro I am getting some very pleasing results. Here is a set of pictures taken at lunch time today at London's famous Borough Market, a food market selling fresh, high-quality and expensive food. Every single picture in this set was taken at ISO 3200, and the colours you see are just as the camera recorded them.
After returning from the shoot I had a message from Jacobs that my new battery grip had arrived. So, with today's release of the Camera Raw update for OS X, I now have everything in place for a complete EOS 5D Mark II workflow. All I need is to take some more pictures…


text:
Cancer & Tumor Markers Catalog
Cancer & Tumor Markers Reagents for Assay Development ISO Certified 13485:2016
Extensive Capabilities & Services
Molecular Reagents qPCR | RT-qPCR | LAMP
Immuno Reagents Antigens | Antibodies | Blockers
ENZYMES •	Hot-Start Taq technologies - chemical, antibody, aptamer •	Lyo & Air-Dryable enzymes (glycerol free) Taq, Bst, RTase •	Thermostable MMLV RT MASTER MIXES •	Lyo & Air-Dryable formats •	Inhibitor-tolerant mixes for stool, sputum, saliva, blood, plant, water. •	For multiplexing, GC-rich templates
VIRUS MANUFACTURING •	Live or inactivated •	Proprietary Ag purification
RECOMBINANT PROTEINS •	 E. coli, P. pastoris, S. cerevisiae , Sf9, Mammalian (CHO, HEK293) •	10L- 130L fermentation ANTIBODIES – MAbs/PAbs •	500+ MAbs produced in grams •	Multi-Kilograms of MIgG / year •	Hundreds of liters of GxhIgG •	Ascites production (55,000 Mice)
NUCLEOTIDES •	dNTPs, Na or Li salts •	Ultra high purity, >99%
Cancer & Tumor Markers - Reagents for Assay Development II
Commercial scale manufacturing of antigens and antibodies with protein purification expertise.
Meridian has been providing innovative life science solutions and building trusted partnerships for over 43 years. Meridian's focus is to offer complete solutions for the development of molecular and immunological assays.
• Full line of immunoassay reagents, including antigens, antibodies and blockers • Large scale production of reagents for molecular assays • Technical support with assay development experience • Dedicated R&D and manufacturing teams • Robust and mature Quality System
ISO Certified 13485:2016
WATERLOO, Belgium
LUCKENWALDE, Germany
MANASQUAN, NJ
CINCINNATI, OH (Headquarters)
CHANGZHOU, China
MODIIN, Israel
Diagnostic Manufacturing | Life Science Manufacturing | Sales & Warehouse
MERIDIAN BIOSCIENCE, INC. Parent Company | Founded in 1977 | Nasdaq: VIVO | 750+ Employees Headquartered in Cincinnati, OH | Presence in 70+ Countries.
INFECTIOUS DISEASE EXPERTISE
Gastro •	 H. Pylori
Tropical •	Zika •	Dengue 1, 2, 3, 4 •	Chikungunya
ToRCH & Childhood •	Toxo •	Rubella •	CMV
Viral Hepatitis •	HAV •	HBV •	HCV •	HDV •	HEV
•	 C. Difficile •	Norovirus •	Adenovirus •	Rotavirus
•	Malaria •	Chagas
•	HSV-1,2 •	Rubeola •	EBV •	Mumps •	Coxsackie •	Rotavirus •	RSV •	Parvo B19 •	VZV
•	Cryptosporidium •	Campylobacter •	 E. Coli
•	Leishmaniasis •	Leptospirosis •	Newcastle Disease •	Yellow Fever •	Nipah Virus •	JEV
•	Salmonella •	 G. Lambia •	Astrovirus
STD •	HSV-1, 2 •	HIV-1, 2 •	HPV •	Syphilis •	Chlamydia •	Neisseria
Respiratory •	SARS-CoV-2
•	 M. Pneumoniae •	 C. Pneumoniae •	Influenza A, B •	Parainfluenza •	 L. Pneumophilia •	RSV •	 M. Tuberculosis •	Streptococcus •	Staphylococcus •	Adenovirus
Cancer & Tumor Markers - Reagents for Assay Development
Cardiac •	Troponin I, T •	Myoglobin •	BNP •	NT-proBNP
Cancer •	CA125 •	CA15-3 •	CA19-9 •	CA72-4 •	CA50 •	CA242 •	Cyfra 21-1 •	CEA
Microbial Detection •	Legionella •	Salmonella •	Cryptosporidium •	 G. Lambia •	 C. Jejuni •	 E. Coli •	Newcastle Disease •	Canine Parvovirus •	Rabies Virus •	Serum Amyloid A (SAA) • Trichomonas foetus •	Nipah •	Transmissible Gastroenteritis Veterinary •	ASFV •	Avian Influenza •	Borrelia •	 Brucella abortus •	Canine Distemper •	Feline Immunodeficiency •	Feline Leukemia •	Foot-and-Mouth •	Canine Heartworm •	Infectious Bursal Disease •	Marek Disease
Drug of Abuse •	Amphetamine •	Barbital •	Benzodiazepine •	Buprenorphine
•	CRP •	PCT •	CK-MB •	D-Dimer
•	Cocaine •	Cotinine •	EDDP
•	Fentanyl •	Ketamine •	K2 •	MDMA (Ecstasy) •	Methadone •	Methamphetamine •	Morphine •	Norketamine •	Opium •	Oxycodone •	PCP
•	Cystatin-C •	Galectin-3 •	Vitamin D •	Apo A, B, E •	NSE •	FABP •	SAH •	MPO •	Fibrinogen •	EGF
•	Thyroglobulin •	erbB-2/HER2 •	AFP •	EGFR
•	HE4 •	NSE •	PMA •	PAP •	PSA
•	PSMA •	S-100 •	PIVKA II •	B2M
•	Lp-PLA2 •	PAPP-A
•	Phenobarbital •	Propoxyphene •	THC
Hormones •	LH, FSH, hCG, •	hGH, AMH
Immunoglobulins/ Blockers •	TRU Block ™ & IgM Diluent •	Animal IgGs – Bovine, Chicken, Goat, Mouse, Rabbit, Sheep •	Human IgA, IgG, IgM, IgE •	Kappa Light chain •	Lambda Light chain •	Goat Anti-Human IgG, IgM, IgA •	Goat Anti-Mouse IgG
Autoimmune •	Jo-1 •	PCNA
Allergens •	Cat & Dog Allergen •	Horse Allergen •	Dust Mite • Alternaria alternate •	Timothy Grass •	 Platanus acerifolia •	Mugwort •	Cortisol •	Estradiol •	Insulin, C-peptide •	Prolactin •	Progesterone •	PTH •	PAPP-A •	TSH, T3, T4, ACTH •	Thyroglobulin
•	pANCA •	cANCA •	Sm Ag •	dsDNA •	La(SSA) •	Ro(SSA) •	Histone •	GMB •	C1q •	Scl-70 •	SS-A •	BS-Gly-1
•	 B. Anthracis •	Clostridium •	Listeria
•	Streptococcus •	Staphylococcus
•	Cathepsin G •	Calprotectin
Respiratory Infections & Diagnosis
Cancer is a leading cause of death worldwide. More than half of all cancer deaths each year are due to lung, stomach, liver, colorectal and female breast cancers. If recent trends in major cancers continue globally in the future, the burden of cancer will increase by 68% over the next 15 years. The high cancer mortality rates are primarily due to a delayed detection of the disease and differences in the policies on cancer screening between countries.
Early detection is the key focus of cancer diagnostics and an early diagnosis makes it possible to cure the disease completely and/or increase survival rates. However, the financial burden associated with the cost of managing and treating cancer is a growing concern. Non-invasive techniques such as serum immunoassays detecting specific tumor markers are highly sought after in order to minimize the costs associated with screening and monitoring the disease. They provide fast, cost-effective, and accurate cancer detection while providing a valuable aid to the clinician and increased comfort to the patient. Cancer biomarkers (also called tumor markers) are proteins produced either by the tumor itself or by the body in response to the presence of cancer. They can be broadly classified into four groups: (1) screening and early detection, (2) diagnostic confirmation, (3) prognosis and prediction of therapeutic response, and (4) monitoring disease and recurrence. Over the past decade, an improved understanding of carcinogenesis and tumor progression has revealed a large number of potential tumor markers. Some markers are associated with only one type of cancer, whereas others are associated with two or more cancer types. No "universal" tumor marker that can detect any type of cancer has been discovered.
FDA Approved Biomarkers for Cancer
Thyroid Cancer (Tg)
Breast Cancer (CA15-3/MUC-1, CA27-29, CEA, erb.2/HER2/new)
Pancreatic Cancer (CA19-9, CEA)
Liver Cancer (AFP)
Colon Cancer (CEA)
Ovarian Cancer (CA125, HE4)
Prostate Cancer (PSA)
VI | Cancer & Tumor Markers for Assay Development
Product Quickfind List
N NGAL/Lipocalin-2. ................................ 19 NSE....................................................... 19 O Osteopontin (OPN)............................... 19 P Pepsinogen I and Pepsinogen II ......... 20 PIVKA-II................................................. 20 Prolactin (PRL)...................................... 20 Prostate Secretory Protein (PSP)......... 20 PSA....................................................... 20 R Retinol Binding Protein 4 (RBP4)......... 21 S S-100. ................................................... 22 Serum Amyloid A (SAA)....................... 22 Sialyl Lewis A and Sialyl Lewis X......... 22 Superoxide Dismutase (SOD).............. 23 T Thymus and Activation Regulated Chemokine (TARC)............................... 23 Thyroid Peroxidase (TPO). ................... 23 Thyroglobulin (Tg)................................. 23 Tissue Transglutaminase (tTG)............. 23 Trypsin. ................................................. 24 TNF-alpha . ........................................... 24 U Urokinase (uPA).................................... 24 V Vitronectin. ........................................... 24
A Alpha 1 Antitrypsin (A1AT)..................... 4 Alpha 2 Macroglobulin (A2M)................ 4 Alpha Fetoprotein (AFP)......................... 4 Amylase.................................................. 5 Apolipoprotein CI (Apo CI). .................... 5 Apolipoprotein E (Apo E)........................ 5 B Beta 2 Microglobulin (B2M)................... 6 C Cadherin-E.............................................. 6 Calcitonin................................................ 6 Calprotectin L1....................................... 6 CA125..................................................... 7 CA15-3/MUC1)....................................... 7 CA19-9.................................................... 8 CA50....................................................... 8 CA72-4 (TAG-72). ................................... 8 CA242..................................................... 8 CEA......................................................... 9 Catalase.................................................. 9 CD1d....................................................... 9 CD3......................................................... 9 CD8....................................................... 10 CD13 (Aminopeptidase N)................... 10 CD15..................................................... 10 CD24..................................................... 10 CD28..................................................... 10 CD30..................................................... 10 CD37..................................................... 11 CD42 .................................................... 11 CD49d................................................... 11 CD57 .................................................... 11 CD59..................................................... 11 CD66b................................................... 11 CD90..................................................... 12 CD105 (Endoglin)................................. 12 CD147................................................... 12 CD177................................................... 12 CD195 (CCR5)...................................... 12 Centromere Protein B (CENPB)........... 13 c-Myc.................................................... 13 Collagen Type VI................................... 13 Cyfra 21-1............................................. 13
D Defensin-beta....................................... 13 Desmin................................................. 14 Disialoganglioside GD2........................ 14 E Elastase................................................ 14 EGFR. ................................................... 14 erbB-2, HER2/neu................................ 15 EpCAM ................................................ 15 F Factor H (Beta 1H). .............................. 15 Factor VIII (FVIII)................................... 15 G GAPDH ................................................ 15 H Heat Shock Proteins. ........................... 16 Hemoglobin.......................................... 16 HE4....................................................... 16 I IGF-I ..................................................... 16 IGFBP-3................................................ 17 Integrin alpha M (CD11b/MAC-1)........ 17 Interferon gamma (IFN-gamma).......... 17 IL-1a and IL-1R .................................... 17 L Lactate Dehydrogenase (LDH)............ 17 Lamin.................................................... 18 Leptin.................................................... 18 Lysozyme............................................. 18 M Microtubule Associated Protein 2 (MAP-2)................................................. 18 Mast Cell Tryptase (MCT).................... 18 Monocyte Chemotactic Protein 1 (MCP-1)................................. 19
Leading Products
Antibodies & Matched Pairs
Alpha Fetoprotein (AFP) M86304M
Epidermal Growth Factor Receptor 2 (ERB2, HER2/NEU) M01296M
MAb (Capture) , ELISA MAb (Detection) , ELISA
M86641M
MAb, ELISA, reacts with peptide ILDV4 (dephosphorylated) MAb, ELISA, reacts with peptide ILDV4 (phosphorylated) MAb, ELISA, reacts with peptide ILDV2 (dephosphorylated) MAb, ELISA, reacts with peptide ILDV2 (phosphorylated)
* Not cross reactive with human albumin. MAM01-210 MAb (Capture) , ELISA MAM01-301 MAb (Detection) , ELISA
Beta 2 Microglobulin (B2M) MCP17-301 MAb, ELISA & RIA * Reacts with soluble B2M and B2M associated with cell-surface MHC Class I molecules and other membrane antigens. CA125 M86306M MAb Group A (Capture) , ELISA & WB M86924M MAb Group B (Detection) , ELISA & WB M86306M MAb Group A (Capture) , ELISA & WB M86429M MAb Group B (Detection) , ELISA & WB * Both pairs detect OC125 (Group A) and M11 (Group B). CA19-9 M66107M MAb (Capture) , ELISA M66106M MAb (Detection) , ELISA M66108M MAb (Alternate Detection) , ELISA M66106M MAb (Capture/Detection) , ELISA M66108M MAb (Capture/Detection) , ELISA * Abs can be used as capture or detection in a sandwich assay. CA72-4 M01341M MAb (Capture) , ELISA M01342M MAb (Alternate Capture) , ELISA M01340M MAb (Detection) , ELISA CEA
HE4 M01323M M01320M M01323M M01321M
MAb (Capture) , ELISA
MAb (Detection) , ELISA Human Hemoglobin (Fecal Occult Blood) H01348M MAb (Capture) , ELISA H01349M MAb (Detection) , ELISA H01416M MAb (Capture) , ELISA H01369M MAb (Detection) , ELISA H01409M MAb (Capture) , LF & Turbidimetry H01410M MAb (Detection) , LF & Turbidimetry Neuron Specific Enolase (NSE) M86101M MAb (Capture/Detection) , ELISA M86520M MAb (Capture/Detection) , ELISA * Abs can be used as capture or detection in a sandwich assay. Pepsinogen I K01402M MAb (Capture) , ELISA & LF K01403M MAb (Detection) , ELISA & LF K01406M MAb (Capture) , ELISA & LF K01407M MAb (Detection) , ELISA & LF Pepsinogen II K01404M MAb (Capture) , ELISA & LF K01405M MAb (Detection) , ELISA & LF
MAM02-008 MAb (Capture/Detection) , ELISA MAM02-009 MAb (Capture/Detection) , ELISA * Abs can be used as capture or detection in a sandwich assay.
MAM02-009 MAb (Capture) , ELISA MAM02-881 MAb (Detection) , ELISA M01250M
MAb (Capture) , ELISA & IHC MAb (Detection) , ELISA & IHC
PIVKA-II M01344M M01343M
* Specific for CEA epitope specificity group I.
Cyfra 21-1 (Cytokeratin 19) M01300M MAb, ELISA & WB M01326M MAb, ELISA
MAb (Detection) , ELISA Prostate Specific Antigen (PSA) Free M92986M MAb (Capture) , ELISA M92396M MAb (Detection) , ELISA * Not cross reactive to Albumin, AFP, CEA, PAP, CA125, CA19-9 or CA15-3. M86506M MAb (Capture/Detection) , ELISA & LF M86806M MAb (Capture/Detection) , ELISA & LF
2 | Cancer & Tumor Markers for Assay Development Cancer & Tumor Markers - Reagents for Assay Development 2
Prostate Specific Antigen (PSA) Total M66276M MAb (Capture) , ELISA & LF M86506M MAb (Detection) , ELISA & LF * Specific for epitope 5 and not cross reactive with human kallikrein 2. M01236M MAb (Capture) , ELISA & LF M86506M MAb (Detection) , ELISA & LF S-100 Beta Q86006M MAb (Capture) , ELISA Q86610M MAb (Detection) , ELISA
Q86003M Q86610M
MAb (Detection) , ELISA * Each capture is specific for alpha-beta and each detection for alpha-beta and beta-beta. Thyroglobulin E01326M MAb (Capture) , ELISA E01325M MAb (Detection) , ELISA * Does not interfere with anti-thyroglobulin auto-antibodies.
Human Antigens (for use as standards, controls & calibrators)
Alpha Fetoprotein (AFP) A32260H
Neuron Specific Enolase (NSE) A86803H
Produced in cell culture, derived from a liver tumor cell and contains approximately 70% of the AFP-L3 isoform, ≥ 95% pure (SDS-PAGE & WB)
From human brain, > 95% pure (SDS-PAGE)
Pepsinogen II A01691H
Purified from human stomach, lyophilized, ≥ 90% pure (SDS-PAGE)
Beta 2 Microglobulin (B2M) A01412H
From human urine, ≥ 98% pure (SDS-PAGE)
From human gastric mucosa, > 90% pure (SDS-PAGE) Purified from human stomach, lyophilized, ≥ 90% pure (SDS-PAGE) PSA, from human seminal fluid, lyophilized, > 95% pure (SDS-PAGE) PSA/ACT Complex, from human seminal fluid and plasma, > 95% pure (SDS-PAGE) PSA, From human seminal fluid, lyophilized, > 98% pure (SDS-PAGE) From human brain tissue, contains both beta-beta and alpha-beta isoforms, > 95% pure From human brain tissue, contains only beta-beta homodimer, > 95% pure (SDS-PAGE)
CA15-3 A32231H CA125 A32180H CA19-9 A86199H A01458H CA72-4 A01723H CA50 A01264H CEA A32030H A38151H
Produced in cell culture, low cross reactivity
A01692H
Prostate Specific Antigen (PSA) A01368H
From native human metastatic liver carcinoma Produced in cell culture, provided as cell culture concentrate
S-100 Beta A86809H
Produced in cell culture, provided as cell culture concentrate
Thyroglobulin H6T08-747
Produced in cell culture, > 50% pure (SDS-PAGE)
From native human liver metastases, > 95% pure (SDS-PAGE)
From human thyroid tissue, > 98% pure (SDS-PSGE) From human thyroid tissue, > 90% pure (SDS-PAGE)
Cyfra 21-1 A32340H
Human Hemoglobin (Fecal Occult Blood) A38192H From human erythrocytes, > 96% pure (SDS-PAGE)
www.MeridianLifeScience.com | 3 w .Merid anLifeScience.com
Alpha 1 Antitrypsin (A1AT)
Abbreviations 6-His – Polyhistidine-tag Aff.Pur. – Affinity Purified, analyte-specific column Ag – Antigen Alk.Phos. – Alkaline Phosphatase conjugated product CLIA – Chemiluminescence Immunoassay CVD – Cardiovascular Disease DB – Dot Blot DFA – Direct Immunofluorescence Assay FC – Flow Cytometry FITC – Fluorescein conjugated product GST – Glutathione S-transferase HRP – Horseradish peroxidase conjugated product IB – Immunoblot
A1AT is a secretory glycoprotein mainly produced in the liver and monocytes. It is the most abundant serine protease inhibitor in human plasma. Several cancers are associated with A1AT deficiency including primary liver carcinoma, lung cancer, bladder cancer and malignant hepatoma. Monoclonals •	Does not cross-react with alpha 1 antichymotrypsin H45200M
Alpha 2 Macroglobulin (A2M)
A2M functions as a universal protease inhibitor in serum and is capable of binding various cytokines and growth factors. Malignant tumors are able to synthesize and release proteins into the circulation, including A2M that protects the tumor against immune system attacks. A common variant of A2M has also been suggested to lead to an increased risk of Alzheimer's disease. Polyclonals CATALOG SOURCE FORMAT APPLICATION L04330G Goat Monospecific IEP Antigens A50114H • Native antigen from human plasma • > 95% pure (SDS-PAGE), lyophilized
ICC – Immunocytochemistry IEP – Immunoelectrophoresis IFA – Immunofluorescence Assay
IgG – Immunoglobin G IgM – Immunoglobin M IHC – Immunohistochemistry IP – Immunoprecipitation LF – Lateral Flow Lysate – Cells which have been lysed MAb – Monoclonal antibody Monospecific – Single band when tested by immunoelectrophoresis Neat – Whole, unpurified, undiluted antisera Neph – Product has been quality controlled by Nephelometry PAb – Polyclonal antibody Purified/IgG – Refer to the Certificate of Analysis regarding the extent of purification and the purification process used. RIA – Radioimmunoassay RID – Radial Immunodiffusion SDS-PAGE – Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis TIA – Product has been quality controlled by Turbidimetry WB – Western blot
Alpha Fetoprotein (AFP)
AFP is a tumor marker used to help detect and diagnose cancers of the liver, testicles, and ovaries. AFP can be fractionated by affinity electrophoresis into 3 glycoforms: L1, L2, and L3. AFP-L3 is specific to malignant tumors. An AFP-L3 test is used to help evaluate the risk of developing hepatocellular carcinoma, especially in those with chronic liver disease, and also to evaluate response of hepatocellular carcinoma to treatment. Monoclonals •	Does not cross-react with human serum albumin •	Suitable for ELISA •	MAbs produced in vivo (unless otherwise noted)
M01254M M01255M M86304B M86641M M86501M
* Also works in LF assays
* Biotin conjugated
* Reacts with AFP Receptor, suited to blocking AFP/ AFP-binding
Alpha Fetoprotein (AFP) continued
Apolipoprotein CI (Apo CI)
Antibody Pairs •	Suitable for ELISA •	MAbs produced in vivo (unless otherwise noted) CAPTURE DETECTION H45610M H45301M
Apo CI is the smallest member of the apolipoprotein family and is mainly distributed on the surface of very low density lipoprotein (VLDL) chylomicrons and high density lipoprotein. Apo CI is a potential serum marker for colorectal cancer, prostate cancer, breast cancer, lung cancer, thyroid carcinoma, malignant pleural mesothelioma, gastric cancer, pancreatic cancer and Wilms' tumor. Polyclonals CATALOG SOURCE FORMAT APPLICATION K74110R Rabbit Aff.Pur. ELISA,IB
* Does not react with human albumin, ferritin, hCG or PSA
MAM01-210 MAM01-301 M86304M M86641M
* Does not react with human albumin
Polyclonals CATALOG
SOURCE FORMAT APPLICATION
K92204R Rabbit
Apolipoprotein E (Apo E)
Antigens A01406H
Apo E is a class of apolipoproteins found in the chylomicron and intermediate-density lipoprotein. It has been linked to cardiovascular disease, Alzheimer's disease, dementia, atherosclerosis, multiple sclerosis, peripheral artery disease, diabetes, stroke, and most recently, cancer, including breast and ovarian cancer. Monoclonals •	Reacts to the E2, E3 and E4 isoforms of apolipoprotein E •	Produced in vivo •	Suitable for ELISA, IHC, IP and WB H06579M
• Native antigen from human cord serum • Suitable for use in ELISA and WB • > 99% pure (SDS-PAGE) • Native antigen from human cord serum • Suitable for use in ELISA and WB • > 99% pure (SDS-PAGE), lyophilized • Native antigen from human hepatocellular carcinoma cell line • Contains approximately 70% of the AFP-L3 isoform • 95% pure (SDS-PAGE) • Suitable for use in ELISA and WB
•	Reacts with VLDL of human plasma •	Suitable for use in ELISA and IHC •	Produced in vivo , lyophilized H61529M Polyclonals CATALOG
Amylase Amylase is produced by the exocrine pancreas and the salivary glands to aid in the digestion of starch. Amylase enzyme levels may be increased in some pancreas, salivary, prostate, lung and ovarian tumors. In general, the blood amylase test is used to help diagnose and monitor acute pancreatitis. Antigens A38120H • Native alpha amylase from human pancreas • Specific activity of 450 Units/mg protein (lot dependent) • Purified and lyophilized
G5C27-766 Goat K34002G Goat K74190G Goat K74180B Goat
Aff.Pur.
ELISA,WB ELISA,WB ELISA,WB
• Native antigen from human plasma (VLDL) • > 95% pure (SDS-PAGE)
• Native alpha amylase from human saliva • Specific activity of 620 Units/mg protein (lot dependent) • > 90% pure (SDS-PAGE), lyophilized • Native alpha amylase from pig pancreas • Specific activity of 640 Units/mg protein (lot dependent) • Purified and lyophilized
A01389P
Product list | Continued
Monoclonals •	Recognizes Cadherin-E expressed on non-neuronal epithelial cells
Beta 2 Microglobulin (B2M) B2M is a protein involved with MHC class I molecules which is found on the surface of almost all nucleated cells. Elevated levels of B2M are noted in lymphoproliferative disorders, neoplasms (malignant and benign), inflammatory disease, and autoimmune diseases such as systemic lupus erythematosus and Sjögren's disease. For cancer, it is not diagnostic for a specific type, but it has been associated with the amount of cancer present (tumor burden) and can be used as a prognostic tumor marker for some blood cell cancers. Monoclonals •	Recognizes the HLA-B2M complex, free or associated with the membrane •	Suitable for use in FC, IHC and IFA •	Lyophilized H42114M •	Reacts with soluble forms of B2M and B2M associated with cell-surface MHC Class I molecules and other membrane antigens •	Suitable for use in ELISA, WB, FC, IP, and RIA MCP17-301 Polyclonals CATALOG SOURCE FORMAT APPLICATION K01372G Goat Aff.Pur. N/A Antigens A01447H • Native antigen from human urine
•	Suitable for use in IHC and IP •	Produced in vivo , lyophilized P91176M
Calcitonin Calcitonin is polypeptide hormone that is produced by the C-cells of the thyroid gland and it acts to reduce blood calcium (Ca2+), opposing the effects of parathyroid hormone (PTH). Calcitonin assay is used to identify patients with nodular thyroid diseases and to diagnose medullary thyroid cancer. Antibody Pairs
•	Suitable for use in CLIA, ELISA and RIA •	Recognizes Native Human Calcitonin CAPTURE DETECTION E01357M E01356M
Calprotectin L1 Calprotectin L1 is a neutrophil-derived protein that can be quantified in the feces and has become an established marker of whole gut inflammation. Fecal calprotectin levels are associated with lifestyle risk factors for colorectal cancer. Antibody Pairs
•	Suitable for use in ELISA with stool samples •	MAbs produced in cell culture, lyophilized CAPTURE DETECTION K01373M K01376M
• Suitable for use in ELISA • 98% Purity (SDS-PAGE)
• Native antigen from human urine • > 98% Purity (SDS-PAGE), lyophilized • Native antigen from human urine • 98% Purity (SDS-PAGE) • Recombinant (E.coli) • 95% Pure (HPLC), lyophilized
•	MAb to Calprotectin •	Produced in cell culture •	Suitable for ELISA and lateral flow CAPTURE DETECTION 9591 9591 Monoclonals •	Suitable for use in ELISA •	Produced in cell culture, lyophilized
Cadherin-E Cadherin-E is a calcium dependent cell adhesion molecule expressed predominately in epithelial tissues. It plays an important role in the growth and development of cells via the mechanisms of tissue architecture and the maintenance of tissue integrity. It is an important determinant of tumor progression, serving as a suppressor of invasion and metastasis (loss of Cadherin-E function promotes tumor progression).
K01374M K01375M
6 | Cancer & Tumor Markers for Assay Development
Cancer Antigen 125 (CA125) A protein in humans that is encoded by the MUC16 gene and found on the surface of many ovarian cancer cells. Monitoring CA125 blood serum levels is also useful for determining how ovarian cancer is responding to treatment and for predicting a patient's prognosis after treatment. CA125 can also be found in other cancers and in small amounts in normal tissue. Antibody Pairs
Cancer Antigen 15-3 (CA15-3 or MUC1) CA15-3 is a tumor marker which corresponds to an immuno- dominant epitope in the extracellular portion of the membrane bound mucin MUC1. It is used to monitor a patient's response to breast cancer treatment and disease recurrence. CA15-3 and the associated CA27.29 are different epitopes on the same gene product. Antibody Pairs •	Binds to an epitope within the VNTR tandem repeat peptide region of MUC1 •	Suitable for use in ELISA and IHC •	MAbs produced in in vivo CAPTURE DETECTION SPECIFIC FOR CA15-3 M86240M M01289M * Underglycosylated M86240M M86240M * Unglycosylated Antigens A32231H • Low cross-reactivity ideal for multi-analyte panels • Suitable for use as a calibrator or control • Suitable for use in CLIA • Cell culture derived protein from human BTA cell line A86153H • Native antigen from human milk
•	Detects both Group A and Group B •	Suitable for use in ELISA and WB •	MAbs produced in in vivo CAPTURE DETECTION M86306M M86924M M86306M M86429M Monoclonals •	Suitable for use in ELISA and WB •	MAbs produced in vivo M86306B
* Specific to Group A, biotin conjugated * Specific to Group B, biotin conjugated
M86429B
• Ovarian Cancer, Calibrator Grade • Low cross-reactivity
• Suitable for use as a calibrator or as an immunogen for antibody development • Suitable for use in CLIA and WB • Cell culture derived protein from human BTA cell line • Native antigen from human fluids • High purity (relative Purity Ratio: > 20,000 Units/mL/OD280nm) • Suitable for use in ELISA and WB
• Suitable for use as a calibrator for single or multiple analyte controls • Low cross-reactivity ideal for multi-analyte panels • Cell culture derived protein
• Cell culture derived protein from ovarian carcinoma cell line • Suitable for use in WB and RIA • Cell culture derived protein from human adenocarcinoma cell line • Suitable for use as a calibrator • Cell culture derived protein from human adenocarcinoma cell line • Suitable for use as a calibrator • > 50% pure (SDS-PAGE) • Partially pure antigen from human fluids • Low cross-reactivity • Suitable for use in ELISA and Electrochemiluminescence assay as a calibrator or control
Please note that cell culture derived antigens offer several advantages over the native fluid versions, including greater availability of the product.
Cancer Antigen 19-9 (CA19-9)
Cancer Antigen CA72-4 (TAG-72)
Also called sialylated Lewis (a) antigen, CA19-9 is a tumor marker used primarily in the management of pancreatic cancer. CA19-9 is also elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer and hepatocellular carcinoma. Apart from cancer, elevated levels may also occur in pancreatitis, cirrhosis, and diseases of the bile ducts. Monoclonals •	Suitable for IHC •	Produced in in vivo M01237M Antibody Pairs •	Suitable for use in ELISA •	MAbs produced in vivo (unless otherwise noted) CAPTURE DETECTION
CA72-4 is a mucinous glycoprotein used as a tumor marker for gastric carcinoma and ovarian cancer (clinical studies demonstrated diagnostic specificity of more than 95%). Elevated CA72-4 levels in serum and plasma have also been reported in other cancers including carcinomas of the pancreas, stomach, gallbladder, colon, cervix and endometrium. There is a good correlation between serologic CA72-4 levels and tumor stage and size. It has been used as an independent marker for the therapeutic monitoring and follow-up care of ovarian cancer patients, in particular in CA125 negative patients. Antibody Pairs
•	Suitable for use in ELISA •	MAbs produced in vivo CAPTURE DETECTION M01341M M01340M M01342M M01340M
M66106M M66108M M66107M M66106M M66107M M66108M M66108M M66106M Antigens A32502H
* Pair does not cross-react CA72-4, PSA, CA125, CA242, and CEA
Cancer Antigen 242 (CA242)
CA242 is related to the sialylated Lewis (a) blood group antigen (Ag-CA19-9) but it is chemically and immunologically distinct. It is used as a tumor marker for the early diagnosis of pancreatic cancer. It has been demonstrated that the CA242 and CA19-9 epitopes are co-expressed on the same mucins, however the detailed structure of the CA242 epitope has not been established. CA242 is suggested to be more specific than CA19-9 in the diagnosis of pancreatic cancer and overall there are differences in the relative expression of CA19-9 and CA242 between benign and malignant diseases and between carcinomas of various organs. Antigens A01267H • Cell culture derived protein • Suitable for use as a calibrator Please note that cell culture derived antigens offer several advantages over the native fluid versions, including greater availability of the product.
• Cell culture derived protein from human adenocarcinoma cell line • Suitable for use in CLIA • Native antigen from metastatic liver carcinoma • Suitable for use as a calibrator and an immunogen for antibody development • Cell culture derived protein • Concentrated (~76,000 U/mL), lot dependent
Cancer Antigen 50 (CA50)
CA50 cancer antigen is a glycolipid and elevated levels of CA50 are found in liver cirrhosis and diseases of the pancreas. CA50 is most prevalent in gastrointestinal cancers, but can also be associated with cancer outside the digestive tract. Antigens A01264H • Cell culture derived protein Please note that cell culture derived antigens offer several advantages over the native fluid versions, including greater availability of the product.
Carcinoembryonic Antigen (CEA) CEA is a type of glycoprotein molecule that is produced by cells of the gastrointestinal tract during embryonic development and CEA is generally present in low levels in the blood. Elevated levels of CEA are detectable in certain types of cancer and to-date CEA is the most widely used tumor marker for assessing prognosis, detecting recurrence and monitoring treatment in people with colorectal cancer. High levels of CEA are also detectable in cancers of the pancreas, stomach, breast, lung, medullary carcinoma of the thyroid, and ovarian cancer. Monoclonals •	Suitable for use in enzyme conjugation, radio-labeling or solid phase immobilization •	Produced in vivo H45655M •	Suitable for use in FC •	Specific for epitope group V M01329M Antibody Pairs
Catalase Catalase is an important enzyme that protects cells from oxidative damage by reactive oxygen species. Catalase is frequently down-regulated in tumors although the underlying mechanism remains unclear. It has been recommended for use as a biomarker for the diagnosis, prognosis, and treatment of breast cancer.
Antigen A50136H
• Native antigen from human erythrocyte • 95% pure (SDS-PAGE) • > 50,000 units/mg protein (lot dependent)
CD1d CD1d encodes a divergent member of the CD1 family of transmembrane glycoproteins, which are structurally related to the major histocompatibility complex (MHC) proteins and form heterodimers with beta-2-microglobulin. Studies have shown that breast cancer cells, through downregulation of CD1d and subsequent evasion of NKT-mediated antitumor immunity, gain increased potential for metastatic tumor progression. Monoclonals •	Suitable for use in IHC and IP •	Produced in cell culture P01242M CD3 CD3 consists of a protein complex with four chains and it is required for T-cell activation. CD3 expression can be detected at all stages of T-cell development. Studies have shown that patients with an unresponsive CD3 receptor have a significantly higher incidence of recurrent head and neck squamous cell carcinoma. CD3 is also under investigation as a target for immunosuppressant therapies for type 1 diabetes and other autoimmune diseases. Monoclonals •	Produced in vivo MAL66-801
•	Suitable for use in ELISA •	MAbs produced in vivo CAPTURE DETECTION MAM02-008 MAM02-009 MAM02-009 MAM02-007 MAM02-009 MAM02-008 MAM02-009 MAM02-881 M01250M M01246M
* Also works in IHC
Polyclonals CATALOG SOURCE FORMAT
K10290G Goat
• Native antigen from human fluids • Suitable for use in ELISA • 98% (SDS PAGE) • Native antigen from human fluids • Suitable for use in ELISA • Purified antigen from cell culture • > 50% pure (SDS-PAGE) • Purified antigen from human colon adenocarcinoma cell line •  95% pure (SDS-PAGE)
CD8 CD8 is a transmembrane glycoprotein that serves as a co-receptor for the T-cell receptor. CD8-positive T-cells represent a major arm of the cell-mediated anti-tumor response and a promising target for developing T-cell-based immunotherapies against lung cancer. The chronic presence of lung tumors induces dysfunctions in CD8-positive T-cells and sensitizes them to activation-induced cell death, which may be associated with poor clinical responses. Monoclonals •	Produced in vivo MAL08-804
CD24 CD24, a heat stable antigen, is a surface marker expressed in many tumor types. It has been identified as a marker of cancer stem cells (CSCs) and several studies suggest that CD24-positive tumors are related to a poor prognosis and for several cancer types. Monoclonals •	Recognizes B-cells from pre-B to mature-B stage
•	Suitable for use in FC and IHC •	Produced in vivo , lyophilized P42118M
CD28 CD28 is one of the proteins expressed on T-cells that provides co-stimulatory signals required for T-cell activation and survival. It is also the receptor for CD80 and CD86 proteins. Studies have shown that it is a marker associated with tumoral expansion in multiple myeloma. Monoclonals •	Induces T-cell proliferation in co-stimulation with CD2 monoclonal antibodies •	Suitable for use in FC •	Produced in vivo P42235M CD30 CD30 is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker. CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma and on classical Hodgkin Lymphoma Reed-Sternberg cells. In 2011, the FDA approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas Monoclonals •	Suitable for use in FC, IHC and IFA •	Produced in vivo , lyophilized P42705M
CD13 (Aminopeptidase N)
CD13 is a Zn 2+ dependent membrane-bound ectopeptidase that preferentially degrades proteins and peptides with a N-terminal neutral amino acid. It has been associated with the growth of different human cancers and is suggested to be a suitable target for anti-cancerous therapy. Monoclonals •	Suitable for use in FC and IHC •	Produced in cell culture, biotin conjugated P01150B
CD15 is a complex cluster of cell surface glycoproteins and glycolipids having a common terminal pentasaccaharide known as the Lewisx (Lex) antigen. In haematopathology, CD15 is important for the diagnosis of classical Hodgkin's disease and the characterization of acute leukemia. CD15 may be used for histopathological grading of gliomas and differentiating between malignant gliomas and non-neoplastic glial cells. Hepatocellular, gastric, and colonic carcinoma and thyroid medullary carcinoma also appear to have worse prognosis if positive for CD15. Monoclonals •	Suitable for use in FC, IHC and IFA •	Produced in cell culture P01158B
10 | Cancer & Tumor Markers for Assay Development r
r rk rs - Reagents for Assay Development
CD37 CD37 antigen is a transmembrane protein of the tetraspanin superfamily that is highly expressed on B-cells during the pre-B to peripheral mature B-cells. In normal tissues, CD37 expression is restricted to lymphoid tissues. However, CD37 is highly expressed on malignant B-cells in non-Hodgkin lymphoma and chronic lymphocytic leukemia which suggests that CD37 could be a promising therapeutic target for B-cell malignancies. Monoclonals •	Suitable for use in ELISA, IHC and IP •	Produced in vivo K8A069M CD42 CD42 is a cell-surface glycoprotein involved in cell–cell interactions, cell adhesion and migration. It participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. Monoclonals
CD57 CD57 is a glycoprotein with cell adhesion functions normally expressed on NK-cells. It serves as a marker of NK cells and neuroendocrine tumors and helps distinguish high grade prostatic adenocarcinoma (CD57-positive) from high grade urothelial carcinoma (CD57-negative). Monoclonals •	Suitable for use in WB, IHC and FC •	Produced in cell culture P01287M CD59 CD59 is a glycoprotein expressed on all human peripheral blood leukocytes, erythrocytes, and several human cell lines. It is a potent inhibitor of the complement membrane attack complex (MAC) action. Its overexpression has been observed in many types of solid cancers, such as pancreatic cancer and lung cancer. Monoclonals •	Reacts with a well-defined epitope (W40, R-53) on CD59 •	Suitable for use in FC and IP •	Produced cell culture MAL59-043 CD66b CD66b, also known as carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8), is expressed mainly on granulocytes such as a GPI anchored molecule and its main functions are cell adhesion, cell migration, and pathogen binding. Under normal conditions, neutrophils have minimal expression of CD66b, however, in chronic myeloid leukemia its expression is upregulated. Monoclonals
•	Specific for CD42b •	Suitable for use in FC •	Produced in vivo , lyophilized N42409M
CD49d CD49d is an integrin alpha subunit composed of a β 4 (CD49d) and a β 1 (CD29) chain and serves as a receptor for fibronectin and VCAM-1. It is normally expressed on monocytes, T-cells, and eosinophils and mainly functions as a cell adhesion and signaling molecule. In cancer, it is an independent prognostic marker for disease progression in patients with chronic lymphocytic leukemia. Monoclonals
•	Suitable for use in FC and IFA •	Produced in vivo , FITC labelled P42531F
•	Suitable for use in FC and IFA •	Produced in vivo , lyophilized P42764M
www.MeridianLifeScience.com | 11 w .MeridianLifeScience.co
CD71 CD71, the transferrin receptor, is involved in the cellular uptake of iron and is expressed on cells with high proliferation. Data suggests that it might be implicated in promoting the growth of endocrine resistance in breast cancer and may serve as a prognostic marker of poor outcome and resistance to tamoxifen. Monoclonals •	Recognizes soluble and bound transferrin receptor •	Suitable for use in ELISA and WB •	Produced cell culture H01372M •	Suitable for use in ELISA and WB •	Produced in vivo H86602M CD90 CD90 is a cell surface glycoprotein involved in cell adhesion and cell communication in numerous cell types, but particularly in cells of the immune and nervous systems. It is widely used as a marker for hematopoietic stem cells and has been identified as a valuable marker to differentiate epithelioid mesothelioma from lung carcinoma. It may also function as a tumor suppressor in nasopharyngeal carcinoma. Monoclonals •	Suitable for use in WB, IFA, FC, and IP •	Produced in cell culture P01283M CD105 (Endoglin) CD105 is an accessory protein of the transforming growth factor-beta receptor system and is expressed on vascular endothelial cells. Studies have identified CD105 expression in several solid tumor types, with the level of expression correlating to various clinicopathologic factors including decreased survival and presence of metastases. It is an independent predictive marker for death risk and unflavorable prognosis in patients with renal cell carcinoma. Monoclonals •	Suitable for use in WB, IP and FC •	Produced in vivo MAL105-226
CD147 CD147, an extracellular matrix metalloproteinase inducer, is correlated with tumor aggressiveness in various human malignanciesis including ovarian and gastric cancers. Its expression is highly associated with cancer invasion and metastasis and it has the potential to serve as a prognostic biomarker (e.g. poor outcome). Monoclonals •	Recognizes an epitope in the N-terminal Ig domain (D1) •	Suitable for use in FC •	Produced in vivo P87535M * Also works in WB and IP
CD177 is an important membrane glycoprotein on neutrophils and serves as a marker for myeloproliferative diseases. Loss of CD177 expression is linked to higher metastasis incidence and shorter survival in breast cancer patients. Monoclonals •	Suitable for use in WB, FC and IP •	Produced in vivo MAL177-166
CD195 (CCR5)
CD195 is a protein on the surface of white blood cells that is involved in the immune system and it acts as a receptor for chemokines, specifically CCL3 (MIP1 α ), CCL4 (MIP1 β ) and CCL5 (RANTES). It is also used by HIV (along with CXCR4) to enter target cells. CD195 has been implicated to play a role in the metastasis of breast cancer and colorectal cancer. Monoclonals
•	Suitable for use in FC •	Produced cell culture P01240M
12 | Cancer & Tumor Markers for Assay Development
ancer Tu or arkers - Reagents for Assay Development
Centromere Protein B (CENPB) CENPB is a highly conserved DNA protein that facilitates centromere formation. It is used as a serologic marker for autoimmune diseases, specifically sclerosis and other rheumatic conditions. It is also a potential biomarker of small-cell lung cancer and a prognostic marker for breast cancer (indicating prolonged survival). Antigens A01375H • Recombinant ( Sf9 Insect Cells) • Suitable for use in ELISA and WB • > 95% pure (SDS-PAGE)
Cyfra 21-1, Cytokeratin 19 Fragment Cyfra 21-1 is a sensitive and specific tumor marker of lung cancer, especially of the squamous cell subtype. An assay for Cyfra 21-1 was first approved by the FDA in 2011 to monitor disease progression and treatment of lung cancer patients. It is also reported to be a potential biomarker for ovarian cancer. Monoclonals •	Suitable for use in ELISA •	Produced in vivo
M01300M Antigens A32340H
• Recombinant ( Sf9 Insect Cells) • Suitable for use in ELISA and WB • 90% pure (SDS-PAGE)
• Native antigen from MCF-7 Cell Supernatant • Calibrator Grade with low cross-reactivity • Suitable for use in CLIA
c-Myc c-Myc a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. A mutated version causing consituative expression of c-Myc is found in many cancers, including Burkitt lymphoma the cervical, ovarian, colon, breast, lung and stomach cancers. Monoclonals •	Produced in vivo MAB07-510 * Suitable for use in WB and IHC Collagen Type VI Collagen Type VI is a widely distributed extracellular matrix macromolecule that plays a crucial role in tissue development and is highly expressed in cancers. Studies show that it promotes chemotherapy resistance, and specifically in breast cancer it regulates cancer progression and metastasis. Antigens A33129H • Native antigen from human placental villi • Suitable for use as a standard, or for antibody production • > 90% pure (SDS-PAGE)
Defensin-beta Human defensins are small cationic peptides produced by neutrophils and epithelial cells and they form two genetically distinct alpha and beta subfamilies. Defensins are involved in various aspects of the innate and acquired immune responses and recently, single nucleotide polymorphisms of beta-defensins have been correlated with increased susceptibility to cancer. Specifically, in oral cancer beta-defensins are down-regulated indicating that it may play a role in tumor suppression. Monoclonals •	Suitable for use in ELISA •	Produced in cell culture, lyophilized EPITOPE BINDING P24141M a.a. 1-36, Defensin-beta 1	* Also works in WB P24011M a.a. 4-41, Defensin-beta 2 Antigens A24100H • Synthetic peptide representing a.a. 4-41 (Defensin-beta 2) • > 95% pure (HPLC), lyophilized A24601H • Synthetic peptide representing a.a. 3-39 (Defensin-beta 4) • > 95% pure (HPLC), lyophilized
www.MeridianLifeScience.com | 13 .MeridianLifeScience.co
Desmin Desmin is a type III intermediate filament in smooth muscle tissue and has a wide variety of functions. Several studies have shown that desmin is a highly sensitive marker for endothelial cell differentiation and tumor invasiveness in several types of cancers, including colon cancer, gastrointestinal stromal tumors, and embryonal sarcoma. Monoclonals •	Produced in vivo MAM26-014
Epidermal Growth Factor Receptor (EGFR) EGF is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Dysregulation of EGF and mutations that lead to EGFR overexpression have been associated with a number of cancers, including lung, breast and anal cancers as well as glioblastoma multiforme. Many therapeutic approaches are aimed at the EGFR such as cetuximab and panitumumab. Monoclonals •	Suitable for use in ELISA (unless stated otherwise) •	Lyophilized •	Produced in cell culture (unless stated otherwise) K67138M * Recognizes the C-terminus a.a. 1165-1186, also works in IB, ICC and IP P24100M * Does not cross-react with v-erb-B, also works in IHC and FC P24200M * Does not cross-react with v-erb-B, also works in IHC and FC K67190M * Recognizes site phosphorylated at Serine 1047, also works in IB, ICC and IP K67902M * Recognizes site phosphorylated at Tyrosine 1173, also works in IB, ICC and IP K67123M * Recognizes site phosphorylated at Tyrosine 845, also works in IB Antigens VTI880 • Recombinant EGF (P. pastoris)
Disialoganglioside GD2
Disialoganglioside GD2 is a sialic-acid bearing glycolipid that is expressed on the surface of all mammalian cells. Studies have shown that they are important target antigens for antibody dependent cellular cytotoxicity of human melanoma and neuroblastoma cells. The relatively tumor-specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T-cell receptors. Antigens A86168H • Native antigen from human brain • > 98% pure (HPTLC), lyophilized
• Suitable for use in WB • 95% pure (SDS-PAGE)
Elastase
VTI882
• Recombinant EGF (P. pastoris) • Suitable for use in WB • > 95% pure (SDS-PAGE)
Elastase is a serine proteinase and specifically the neutrophil form of Elastase is 218 amino acids long, with two asparagine- linked carbohydrate chains. It is secreted by neutrophils and macrophages during inflammation to destroy bacteria and host tissue. Research has shown that neutrophil Elastase can speed up the progression of cancer and the amount of immunoreactive neutrophil Elastase in tumor tissue is an independent prognostic indicator of patients with breast cancer and lung cancer. Antigens A01683H • Native antigen from human neutrophils • Suitable for use in ELISA and WB • 90% pure SDS-PAGE (Chromatography) A50145H • Native antigen from human neutrophils • > 95% pure (SDS-PAGE), lyophilized
Cancer & Tu or Markers - Reagents for Assay Development
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32


text:
A Scottish case: Highland fling
By Tony Bingham2014-10-31T06:01:00+00:00
What happens when a high-level solicitor comes up against a determined Scottish subbie?
In this dispute it's not easy to tell who won the competition. It was a competition designed to decide who made who more fed up. On one side the M&E subcontractor T Clarke (Scotland) Ltd, and their solicitors Brodies; on the other side under-floor sub-subcontractor MMAXX Underfloor Heating Ltd, owned by Neil McFarlane. Now then, Brodies are one of the top-notch solicitors in Scotland and construction is right up their street. Moreover, they know their adjudication territory, with massive experience.
Their opponent is not a solicitor, has no legal qualifications, and no in-depth knowledge of this adjudication malarkey. Neil McFarlane is just one of those every day construction blokes who knows every ounce of under-floor heating stuff and puts his heart and soul into making his business survive. McFarlane against T Clarke, with Brodies at their side, stood no chance when Brodies started to run rings around him with their legal know-how.
But McFarlane stood up to them. He gave them building industry know-how. He began to run rings around the other side's legal team with sheer awkwardness. The two sides were not just at loggerheads, they became two Scottish clans utterly determined to defeat the other. As for the actual dispute about the monies said to be due on the account - tosh. It was the fight that mattered, a fight that went into the Scottish High Court and then into the Scottish Court of Appeal.
Seemingly the sub-subcontract included supply and install heat pumps and under -floor heating. The relationship quickly soured said the first judge. McFarlane became fed up waiting for his money. He had heard of this adjudication thing, so triggered the starting pistol. I told you - Brodies are damn good. The adjudication was torpedoed soon after it started. They argued to the adjudicator that he had no jurisdiction because McFarlane messed up the machinery for getting started. The adjudicator packed up. This McFarlane Scottish warrior chap didn't understand all this lawyer footwork and became furious. Anyway he came again with adjudication number two and, once again, Brodies got the next adjudicator to soon clear off on technicalities.
This McFarlane Scottish warrior chap didn't understand all this lawyer footwork and became furious. Then he came again with another adjudication
Can you hear the steam coming out of the sub-subcontractor's loins? Anyway he came again. It was adjudication number three. McFarlane claimed £184,740 but Brodies persuaded the adjudicator not to go away, but to award a mere £17,000. I don't know why but I do suspect that a talented set of lawyers versus the subbie isn't much of a contest. McFarlane came with adjudication number four. That's because he believed he had another good claim. Brodies persuaded the adjudicator to clear off, so he began number five. He is a toughie and I bet he will keep coming. That adjudication was completed and McFarlane lost. So T Clarke began adjudication number six and this time they lost.
I bet McFarlane was "cock-a-hoop" (that's a Scottish noise for "yah-boo-sucks"). Hell, McFarlane started adjudication number seven and Brodies persuaded the adjudicator to go away by telling him McFarlane was unlikely to pay his fees. McFarlane came with adjudication number eight (the man is unstoppable). And, you guessed it, Brodies persuaded the adjudicator to go home. Damn it. McFarlane came with number nine and Brodies got that adjudicator to resign. Imagine how this sub-subcontractor fellow felt?
McFarlane deployed some tactics of his own. Bear in mind that the work itself is still on-going, or rather, the heat pumps are still being installed.
Bear in mind too that any delay can easily torpedo the main contractor's programme. McFarlane adopted a non-cooperation attitude. He is alleged by T Clarke to have refused to address a health and safety issue that arose when a hose on his drilling rig failed. He threatened to walk off site because he knew that would terrify everyone. He logged unjustified (said Brodies) notices of delay; he bombarded T Clarke with correspondence; he claimed new payment terms applied and more besides. In short, he became, according to some, a damn nuisance at ground level. Mind you, he was saying something similar about the highfalutin legal stuff coming at him.
Then Brodies tried something novel. They went to the High Court for an Order banning McFarlane coming with more adjudications - it was costing T Clarke a mint in legal fees. McFarlane had got to the point that he and his company MMAXX could not give a damn. The judge at the first court said it would be wrong and unlawful to bar this robust McFarlane fellow coming to adjudication. The Court of Appeal said the same. So, Mr McFarlane can keep coming, keep mithering, bothering, poking. The Act of Parliament for adjudication is almost unstoppable.
So who won? Brodies are far ahead of McFarlane in being clever construction lawyers. But McFarlane is far, far ahead of Brodies when it comes to under-floor heating. After all that's what T Clarke and Mr McFarlane were trying to get done. I nearly forgot.
Tony Bingham is a barrister and arbitrator at 3 Paper Buildings, Temple
The CIOB has been trying to root out corruption in the industry but how deeply ingrained is the problem?
Planning infrastructure: Looking into the future
The EEF has echoed the recommendations of the Armitt Review to create an independent body to plan long-term infrastructure projects
Prefabrication: Off-site on your mind
Complex projects are increasingly relying on off-site manufacturing to help deliver schemes on time and budget. But a new kind of supply chain creates new kinds of risks
More Comment
Government rightly stepped in to tackle overheating in homes
Demonstrating compliance with the new Part O building regulation should be a priority now for housebuilders
Corruption in construction: it isn't always obvious
Anita Clifford advises firms to implement robust measure to combat fraud and bribery even in its most subtle forms
Does Gove's £4bn cladding levy mark the start of an anti-development era?
Unable to get more Treasury funding, the secretary of state has found a convenient punch bag and housebuilders could be left reeling for years


Keeping Secrets, 6" x 6" x 2"
I am excited to be exhibiting my new type of artwork at Fountainhead Gallery in Seattle for the month of June. I will be exhibiting along with three other artists June 7 through 30, with an opening reception Saturday evening June 9 from 5 to 7 p.m.
These new shadowbox artworks evolved from my desire to make something with my collection of natural objects. The eroded seashells, corals, limestone deposits and bits of driftwood that I pick up on the beach have such pleasing sculptural forms that I consider them works of art on their own. I was tempted to present them on pedestals with no artistic intervention. Removing the object from its original environment puts it into a new context and can generate appreciation for its abstract form, curiosity about what it is, and what its symbolic meaning is. In arranging and juxtaposing the objects I soon started to see them as players in a mysterious drama.
My late mother was an accomplished artist who created paintings, sculptures, theatrical works and children's books. Having studied at the acclaimed experimental art school Black Mountain College, she was constantly trying new techniques, despite the limitations of living in a small Southern town. Puppetry was a medium she had a love for since childhood, with which she could combine the skills of building the puppets and sets along with writing the plays. She eventually formed a troupe which traveled regionally, presenting her original works. As a teen I was prevailed upon one summer to perform one of her plays.
While I admired my mother's expressive style and have painted my own versions of one of her motifs, the broken conch shell, my own artistic temperament is more restrained and classically inclined than hers. Having thought of myself as a creator of two-dimensional art, I was surprised to find myself making constructions that could be seen as small theaters, with found and crafted objects acting as setting and characters. It felt entirely natural to sculpt small heads to include, and I recalled making puppets with the other children in a workshop my mother taught.
The disembodied heads are not making their first appearance in my work. In the 1990s I was painting surrealistic scenes in which the egg-shaped, disembodied head represented the subconscious or dream state. It has a pleasing form and introduces a human element into a composition. In these new works, it represents a meditative state or a place to which the mind has traveled.
In addition to the sculptural, natural and found elements, I am incorporating landscape painting as a backdrop in some of the constructions. I have primarily exhibited landscape paintings for several years. In the interest of recycling, in a few shadowboxes I use sections of older paintings. Creative re-use and a reluctance to add to the waste stream are growing concerns of mine. These works evolved organically into scenes from stories without words, involving the cycle of life, nature and psychic states. I will be interested to see what my audience thinks of them!
I am pleased to have a painting selected by guest juror Deborah Paine for the annual Center on Contemporary Art members' show. CoCA's exhibits are always lively and progressive, and usually include something you've not seen the likes of before. While the Seattle organization has been around for years, it has had to move its physical space around a lot, and I have been impressed at its tenacity in presenting ambitious exhibits in difficult economic times. The new gallery space is in the Toshiro Kaplan building (114 3rd Ave. S.) in Pioneer Square and has been freshly renovated. There will be an opening reception during the monthly artwalk, Thursday April 6, from 6 to 9 p.m. The show will be up until Saturday, April 29. For more information, see the webpage at CoCA Members' Show .
At left: Flood, oil and aluminum leaf on panel, 14" x 14"
The Raven Speaks, 6" x 6"
Each December the Fountainhead Gallery hosts a group show of gallery artists, with an inspirational theme. This year the theme is "Celebrating the Poetic Heart," and artists were asked to submit works that were inspired by a poem. I admire poetry, but don't read much of it. While painting, I often fixate on music and the poetry and creativity in a lyric, and I happened to have a new piece I made while thinking about a song by the Pixies. I will be exhibiting it and a few other new tiny works, which are a departure from the paintings in my recent exhibits. These combine oil painting with metal leaf in silver, gold or aluminum. I have been experimenting with both translucent paint on top of the leaf, and with the more traditional method of gilding only the background. For subject matter, I am continuing to be drawn to the surface of the sea and also to sea creatures and birds.
The exhibit will run December 1 - 23, and there will be an opening reception with music, refreshments and poetry readings on Saturday, December 3 from 5 to 7 p.m. All are welcome. For more information, call 206-285-4467, or go to Fountainhead Gallery.
My large painting Mired (oil on canvas, 34" x 40") has a prominent location in the installation of the Columbia City Gallery's annual juried show. The exhibit has the theme "H2O: What is it worth?" and was juried by Greg Lundgren (curator), Merica Whitehall (Executive Director of the Nature Consortium), and Vaughn Bell (environmental artist). The chosen artworks are diverse in media and style, ranging from conceptual projects, to sculptures in materials both ancient and modern, to traditional oil painting. The ideas represented are similarly wide-ranging. The opening reception August 20 was well-attended. It is well worth a visit to the charming Columbia City neighborhood to see the show before it closes September 25. The gallery is located at 4864 Rainier Avenue South, Seattle 98118. Phone: 206-760-9843.
During the past year I spent some months experimenting with media such as metal leaf, pondering making sculptural constructions, and painting the figure model. But when it came time to settle down and choose a theme for my next show at Fountainhead Gallery, I was pulled back to painting sea, sky and rock. As I point out in my artist's statement, this subject matter, while representational, is contemplative and lends itself to minimalism, manipulations of composition and experimentation with color.
 I have admired the work of Vija Celmins, whose highly rendered drawings of the surface of the sea are impressive technically and conceptually. I was challenged to do my version, the result being "Deep Blue", 30" x 40", with a large sea surface and a high horizon line. As a companion, I composed "Traversing the Unknown", a seascape with a low horizon line and a massive cloud picking up varied colors of the setting sun. I don't like to repeat myself; I tend to proceed in a theme and variation manner when composing new works.
detail, Realm, oil on canvas, 32" x 26"
In 2006 my husband and I toured the Galapagos Islands for a week in one of the smaller available tourist boats and were properly impressed by the primordial scenery and wildlife. The islands were composed of jagged outcroppings of volcanic rock, and the birds and animals were unafraid of humans. We were able to get close to the iconic giant tortoises, sea lions, marine iguanas, blue-footed boobies and even nesting albatross. The Ecuadorian government has established policies to reduce the impact of current tourism and to ameliorate damage from past exploitation. I carried a little sketchbook and watercolor set along with my camera and captured a small portion of the wonderful experience, but had not made use of any of the images until recently. Having made a painting of a rugged part of the Olympic Peninsula coast for my exhibit last year, I continued with three based on scenes of rocks jutting from the sea in the Galapagos. I recall one particularly thrilling dawn, when our boat sailed through a narrow passage between two towering spires.
 Also in this show is a painting of an iguana isolated on a tiny island of rocks (Realm, 32" x 26"). I chose a green (land) variety of iguana for my protagonist; the marine variety are phenomenally ugly.
 Having created several compositions of rocks surrounded by sea, for the last painting I finished for the show, I chose to depict water surrounded by rock. In some parts of our world, the coasts are being inundated by rising seas, in others drought is leaving precious little water. A location I visited in Iceland in 2011 provided a good illustration of this—a deep crater in the rocky, treeless terrain, filled with a mysterious pool of water. I added one of the hardy Icelandic ponies to the scene (Iceland Eye, 30" x 24").
This describes a few of the ten paintings in "Vistas", which will be on view at the Fountainhead Gallery, 625 W. McGraw St., Seattle, from June 2 to 25, 2016. Also exhibiting are Jennifer Frohwerk with narrative interior scenes and still life artist Beth Flor. There will be an artists' reception open to the public on Saturday, June 4, from 5 to 7 p.m., and all are invited.
Murmur and Sigh, oil on canvas, 28" x 36"
I have a painting included in Gallery 110's 6th Annual Juried Exhibit, which will be on view for the month of February. The exhibit was curated by Melissa Feldman, a faculty member of Cornish College of the Arts. After choosing from over 1,500 submitted works from around the nation (they used the Call for Entry online submission system), she titled the exhibit "Beam Me Up" and noted the process was "like receiving messages from sentient life on other planets." I imagine sorting through that many entries would be fascinating but exhausting. Trends she recognized included the "zen aesthetics of minimalism", which I would say my piece, Murmur and Sigh, represents.
Gallery 110 is an artist-run, nonprofit space in Pioneer Square's Toshiro Kaplan building, one of the best places to find a full gamut of art in Seattle. The gallery has just been remodeled and will be fresh and bright for the installation of the new show. I look forward to seeing the other works in the exhibit. Other than regular hours, Gallery 110 will be open for the First Thursday Artwalk this week (Feb. 4) and there will be a reception and awards presentation on Saturday, February 6, from 5 to 7, to which the public is also invited. For more information, go to Gallery 110.
I enjoy participating in themed exhibits when the theme relates to my work; it's fun to see the variety of viewpoints on the subject and how my entry contributes. Curators Megan Somerville-Loomis and Ted Loomis of ArtEAST have chosen one of my paintings along with 27 others for an exhibit that explores clouds-- "Mirroring our own brief journeys, clouds' temporal existence reflects our dreams and drives our imagination."
I helped the curators to install the artworks in Blakely Hall, community center of the Issaquah Highlands, about 30 minutes east of Seattle. With diversity in size, media and mood, it was a challenge, but the final arrangement complements the works. There will be a reception with live music, a poetry reading based on the paintings, and a talk on creativity by Obadinah Heavner on Saturday, January 23, from 6 to 8 p.m. The exhibit will be up until March 14. For more information, go to ArtEAST.
At left: Pirouette, oil on canvas, 40" x 24"
Burning Sky with Orchids, oil, 23" x 25"
Feeling the unusually tropical heat in Seattle this summer? Visit the Coastal Kitchen restaurant in Capitol Hill for their Caribbean Seas Tour and some spicy seafood. To go along with the currently featured island region's menu, the restaurant's curator chose three of my paintings for an exhibit decorating the dining rooms. The works will be hanging through November 8, 2015. The popular restaurant is located at 429 15th Avenue East. Go to Coastal Kitchen for more information.